

产品名称：噻氯匹啉盐酸盐

产品别名：盐酸噻氯匹啉； Ticlopidine hydrochloride

生物活性：

生物活性:																									
Description		Ticlopidine hydrochloride is an adenosine diphosphate (ADP) receptor inhibitor against platelet aggregation with IC50 of ~2 μM. Target: Adenosine diphosphate (ADP) Ticlopidine (trade name Ticlid) is an antiplatelet drug in the thienopyridine family. Ticlopidine hydrochloride inhibits platelet aggregation with IC50 of ~2 μM in men. Like clopidogrel, it is an adenosine diphosphate (ADP) receptor inhibitor. It is used in patients in whom aspirin is not tolerated, or in whom dual antiplatelet therapy is desirable. Because it has been reported to increase the risk of thrombotic thrombocytopenic purpura (TTP) and neutropenia, its use has largely been supplanted by the newer drug, clopidogrel, which is felt to have a much lower hematologic risk. Its niche role as an alternative in those patients who do not tolerate Clopidogrel has now been superseded by Ticagrelor and Prasugrel. The usual dose is 250 mg twice daily by the oral route. Ticlopidine hydrochloride, when orally administered to rats, results in activation of basal and prostaglandin E1 (PGE1)-stimulated adenylate cyclase activity through increase in affinity of the cyclase in platelet membrane to PGE1, although it failed to affect adenosine- or sodium fluoride-stimulated activity of the enzyme.																							
Solvent&Solubility		In Vitro: DMSO : 83.3 mg/mL (277.44 mM; Need ultrasonic) <table><tr><td rowspan="4">Preparing Stock Solutions</td><td>Solvent Concentration</td><td>Mass</td><td>1 mg</td><td>5 mg</td><td>10 mg</td></tr><tr><td>1 mM</td><td></td><td>3.3306 mL</td><td>16.6528 mL</td><td>33.3056 mL</td></tr><tr><td>5 mM</td><td></td><td>0.6661 mL</td><td>3.3306 mL</td><td>6.6611 mL</td></tr><tr><td>10 mM</td><td></td><td>0.3331 mL</td><td>1.6653 mL</td><td>3.3306 mL</td></tr></table> *请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限 -80℃, 6 months; -20℃, 1 month。 -80℃ 储存时，请在 6 个月内使用， -20℃ 储存时，请在 1 个月内使用。			Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg	1 mM		3.3306 mL	16.6528 mL	33.3056 mL	5 mM		0.6661 mL	3.3306 mL	6.6611 mL	10 mM		0.3331 mL	1.6653 mL	3.3306 mL
Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg		10 mg																			
	1 mM		3.3306 mL	16.6528 mL		33.3056 mL																			
	5 mM		0.6661 mL	3.3306 mL		6.6611 mL																			
	10 mM		0.3331 mL	1.6653 mL	3.3306 mL																				
References		[1]. Thebault JJ, et al. Effects of ticlopidine, a new platelet aggregation inhibitor in man. Clin Pharmacol Ther. 1975 Oct;18(4):485-90. [2]. Ashida SI, et al. Mode of action of ticlopidine in inhibition of platelet aggregation in the rat. Thromb Haemost. 1979 Apr 23;41(2):436-49.																							